Currently, there are 160.42M common shares owned by the public and among those 146.57M shares have been available to trade.
The company’s stock has a 5-day price change of -20.63% and -27.54% over the past three months. NVAX shares are trading -25.37% year to date (YTD), with the 12-month market performance up to 25.52% higher. It has a 12-month low price of $3.81 and touched a high of $23.86 over the same period. NVAX has an average intraday trading volume of 4.29 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.74%, -25.46%, and -42.78% respectively.
Institutional ownership of Novavax, Inc (NASDAQ: NVAX) shares accounts for 59.79% of the company’s 160.42M shares outstanding.
It has a market capitalization of $965.06M and a beta (3y monthly) value of 3.14. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.83% over the week and 5.40% over the month.
Earnings per share for the fiscal year are expected to increase by 81.77%, and 342.99% over the next financial year. EPS should grow at an annualized rate of 67.92% over the next five years, compared to 25.88% over the past 5-year period.
Looking at the support for the NVAX, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on February 28, 2025, with the firm’s price target at $19. JP Morgan coverage for the Novavax, Inc (NVAX) stock in a research note released on July 30, 2024 offered a Underweight rating with a price target of $8. JP Morgan was of a view on May 10, 2024 that the stock is Neutral, while BofA Securities gave the stock Neutral rating on May 10, 2024, issuing a price target of $4- $12. B. Riley Securities on their part issued Buy rating on August 09, 2023.
